CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended		98 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
OPERATING ACTIVITIES
Net loss	$ (2,830)	$ (7,022)	$ (149,222)
Non cash items:
Deferred tax expense	0	0	770
Depreciation and amortization, net of gain on sale	(14)	90	3,928
Non-cash stock compensation	104	133	4,928
Gain on sale of bone device business	0	0	(2,298)
In-process research and development	0	0	34,311
Change in other operating items:
Interest, income taxes and other current assets	428	434	1,378
Accounts payable	132	91	(762)
Accrued liabilities	(37)	(486)	(3,012)
Cash flows used in operating activities	(2,217)	(6,760)	(109,979)
INVESTING ACTIVITIES
Expenditures for furniture and equipment, net	0	(19)	(1,044)
Proceeds from sale of assets	172	0	7,172
Cash paid for assets of AzERx/CBI	0	0	(4,058)
Cash paid for patent rights	(378)	0	(1,028)
Purchases of investments	0	0	(282,538)
Maturities of investments	0	0	340,476
Cash flows (used in) provided by investing activities	(206)	(19)	58,980
FINANCING ACTIVITIES
Net proceeds from stock option exercises	0	0	4,612
Net proceeds from sale of stock	0	0	3,376
Common stock purchases	0	0	(1,041)
Cash flows provided by financing activities			6,947
NET DECREASE IN CASH AND CASH EQUIVALENTS	(2,423)	(6,779)	(44,052)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	13,778	24,387	55,407
CASH AND CASH EQUIVALENTS, END OF PERIOD	11,355	17,608	11,355
Supplemental Disclosure of Non-Cash Investing Activities -
Cash paid	0	0	4,058
Lipimetix [Member]
INVESTING ACTIVITIES
Cash paid for assets of AzERx/CBI	(378)		(4,436)
Supplemental Disclosure of Non-Cash Investing Activities -
Current assets acquired	0		29
Patent rights acquired	1,045		3,187
Liabilities acquired, and accrued acquisition costs	0		(457)
Original investment reversal	0		(750)
In-process research and development acquired	0		34,311
Noncontrolling interest	(667)		(667)
Common stock issued for acquisition	0		(31,217)
Cash paid	$ 378		$ 4,436